De Vinci, C, Levine, P H, Pizza, G et al. · Biotherapy (Dordrecht, Netherlands) · 1996 · DOI
This small study tested whether Transfer Factor (TF), a substance derived from immune cells, could help people with ME/CFS feel better. Twenty patients received either TF or a placebo, and researchers tracked their symptoms and blood levels of viruses linked to ME/CFS. Twelve patients showed improvement within 3-6 weeks of starting treatment, though the study was too small to prove TF definitely works.
This study addresses the persistent question of whether immune-modulating interventions can benefit ME/CFS patients, particularly those with suspected herpesvirus reactivation. The finding that clinical improvement occurred without clear serological changes may shift how researchers think about measuring treatment response in ME/CFS.
This pilot study does not prove Transfer Factor is an effective ME/CFS treatment—the small sample size, lack of details about blinding quality, and absence of long-term follow-up data are significant limitations. The correlation between symptom improvement and serological changes (or lack thereof) does not establish causation. Results cannot be generalized beyond this specific population without larger, well-designed trials.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.